PubMed · 11575714
Donitriptan (Pierre Fabre).
Abstract
Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development [396027]. This compound has an increased potency and, importantly, markedly higher intrinsic activity in comparison to the well described tryptamine derivatives, naratriptan, zolmitriptan and sumatriptan [295769].
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
M Dukat. 2001. Donitriptan (Pierre Fabre).. https://pubmed.ncbi.nlm.nih.gov/11575714/
Cite the original work for its findings. Save a collection to share your selection of sources.